secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001171843-25-007256
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive
--------------------------------------------------------------------------

- Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.
- Revenue fell to $0.5M from $1.3M due to lower Alnylam ONPATTRO royalties.
- Cash, equivalents and marketable securities $93.7M at Sep 30, 2025, down from $122.6M at Dec 31, 2024.
- Moderna US trial set for March 2026; Pfizer-BioNTech claim construction ruling favorable in Sep 2025.
- Imdusiran: 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up off treatment up to 2+ years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/0001171843-25-007256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/f8k_111325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer